DB05530InvestigationalNucleic Acid Based Therapies
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with...
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C) and viral infection.Curator reviewed
- Code names
- CPG 10101
Resolves to
Compound
Targets
What you can answer from here — as of April 23, 2025
Which drugs share a target with CPG 10101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account